Clinical correlates
| Title: | Clinical correlates |
|---|---|
| Patent Number: | 8,765,366 |
| Publication Date: | July 01, 2014 |
| Appl. No: | 12/293249 |
| Application Filed: | March 16, 2007 |
| Abstract: | A method of assessing an intracellular pathogen infection and/or monitoring an intracellular pathogen infection in an individual comprises determining whether the individual has (a) T-cells that secrete IFN-γ only, (b) T-cells that secrete IL-2 only or (c) T-cells that secrete both IFN-γ and IL-2 in response to an intracellular pathogen antigen and optionally determining any change in this cytokine profile. |
| Inventors: | Lalvani, Ajit (Oxford, GB); Millington, Kerry (London, GB) |
| Assignees: | Lalvani, Ajit (Oxford, GB) |
| Claim: | 1. A method for assessing and/or monitoring a Mycobacterium tuberculosis infection in an individual, said method comprising: (i) contacting a T-cell containing sample from said individual with a mycobacterial antigen, wherein the mycobacterial antigen is a peptide which is recognized by a T-cell and wherein the T-cell recognizes a natural T-cell epitope sequence in a naturally occurring Mycobacterium tuberculosis protein; (ii) detecting any cells that secrete IFN-γ and/or IL-2′ (iii) determining: (a) whether the sample comprises cells that secrete IFN-γ only; (b) whether the sample comprises cells that secrete 11-2 only; and (c) whether the sample comprises cells that secrete both IFN-γ and IL-2, (iv) inferring the mycobacterial load in the individual, wherein the proportion of (a) is positively correlated with mycobacterial load, the proportion of (b) is negatively correlated with mycobacterial load, and the proportion of (c) is negatively correlated with mycobacterial load; wherein the profile of cells that secrete IFN-γ only, ells that secrete IL-2 only, and cells that secrete both IFN-γ and IL-2 indicates the status of the infection as follows: (A) where an individual has recovered from tuberculosis, the likelihood of reactivation of the disease is positively correlated with (a) and negatively correlated with (b) and (c); (B) where an individual has tuberculosis, untreated disease is positively correlated with (a) and negatively correlated with (b) and (c), whereas treated disease is positively correlated with (b) and (c) and negatively correlated with (a); (C) where an individual has tuberculosis infection, active disease is positively correlated with (a) and negatively correlated with (b) and (c), whereas latent infection is positively correlated with (b) and (c) and negatively correlated with (a); (D) where an individual has a latent tuberculosis infection but no disease symptoms, the risk of progression or reactivation of the infection is positively correlated with (a) and negatively correlated with (b) and (c), such as in recently exposed individuals; (E) where an individual is being treated for tuberculosis infection, the success of the treatment correlates positively with (b) and (c) and negatively with (a). |
| Claim: | 2. A method according to claim 1 (E), wherein said individual has received a drug or vaccine which treats said infection. |
| Claim: | 3. A method according to claim 2 , further comprising comparing the status of said infection to the previously determined status of said infection in said individual, thereby monitoring the effectiveness of said drug or vaccine in said individual. |
| Claim: | 4. A method according to claim 1 (E), wherein said individual has received a test drug or vaccine intended to treat said infection. |
| Claim: | 5. A method according to claim 4 , further comprising comparing the status of said infection to the previously determined status of said infection in said individual, thereby determining the efficacy of said test drug or vaccine. |
| Claim: | 6. A method according to claim 1 , wherein the individual is human or mammal. |
| Claim: | 7. A method according to claim 1 , wherein said individual has active TB disease or latent tuberculosis infection (LTBI). |
| Claim: | 8. A method according to claim 1 , wherein said individual is at risk of contracting said infection. |
| Claim: | 9. A method according to claim 1 , wherein the antigen is ESAT-6 or CFP-10 or another mycobacterial antigen. |
| Claim: | 10. A method according to claim 1 , wherein the antigen is a fragment or homologue of a naturally occurring Mycobacterium tuberculosis protein which is recognized by a T-cell which recognizes a natural T-cell epitope sequence in the protein. |
| Claim: | 11. A method according to claim 1 , wherein (a), (b) and (c) are detected using immobilized antibodies to IFN-γ and IL-2. |
| Claim: | 12. A method according to claim 1 , wherein said sample comprises freshly isolated T-cells or T cells after being frozen. |
| Claim: | 13. A method according to claim 1 , wherein said sample comprises T-cells that have been cultured in vitro. |
| Claim: | 14. A method according to claim 1 which is carried out to: (i) predict development and/or reactivation of tuberculosis; (ii) monitor anti-tuberculosis therapy; (iii) evaluate the efficacy of an anti-tuberculosis drug or vaccine; or (iv) determine whether anti-tuberculosis therapy results in a sterilising cure. |
| Claim: | 15. A method according to claim 1 wherein the individual is a small child and/or is immunocompromised. |
| Claim: | 16. A method according to claim 1 wherein the monitoring method defined in claim 14 is carried out at multiple time intervals to determine a change in status of the infection. |
| Claim: | 17. A method according to claim 16 wherein the monitoring method is carried out at least 3 to 20, preferably 6 to 10, times and/or is carried out at least every 40 days and/or for the duration of the period of risk of reactivation and/or is carried out to determine if latent tuberculosis is becoming active. |
| Claim: | 18. A method for assessing and/or monitoring a Mycobacterium tuberculosis infection in an individual, said method comprising: (i) contacting a T-cell containing sample from said individual with a mycobacterial antigen; (ii) detecting any cells that secrete IFN-γ and/or IL-2; (iii) determining: (a) whether the sample comprises cells that secrete IFN-γ only; (b) whether the sample comprises cells that secrete IL-2 only; and (c) whether the sample comprises cells that secrete both IFN-γ and IL-2, (iv) inferring the mycobacterial load in the individual, wherein the proportion of (a) is positively correlated with mycobacterial load, the proportion of (b) is negatively correlated with mycobacterial load, and the proportion of (c) is negatively correlated with mycobacterial load; wherein the profile of cells that secrete IFN-γ only, cells that secrete IL-2 only, and cells that secrete both IFN-γ and IL-2 indicates the status of the infection as follows: (A) where an individual has recovered from tuberculosis, the likelihood of reactivation of the disease is positively correlated with (a) and negatively correlated with (b) and (c); (B) where an individual has tuberculosis, untreated disease is positively correlated with (a) and negatively correlated with (b) and (c), whereas treated disease is positively correlated with (b) and (c) and negatively correlated with (a); (C) where an individual has not received treatment for tuberculosis infection, active disease is positively correlated with (a) and negatively correlated with (b) and (c), whereas latent infection is positively correlated with (b) and (c) and negatively correlated with (a); (D) where an individual has a latent tuberculosis infection but no disease symptoms, the risk of progression or reactivation of the infection is positively correlated with (a) and negatively correlated with (b) and (c), such as in recently exposed individuals; (E) where an individual is being treated for a tuberculosis infection, the success of the treatment correlates positively with (b) and (c) and negatively with (a), wherein the antigen is a peptide of a naturally occurring Mycobacterium tuberculosis protein which is recognized by a T-cell which recognizes a natural T-cell epitope sequence in the protein. |
| Current U.S. Class: | 435/4 |
| Patent References Cited: | 6218132 April 2001 Spack et al. 2002/0032162 March 2002 Content et al. WO 98/23960 June 1998 WO 02/054072 July 2002 |
| Other References: | Emu B., et al (Journal of Virology 79(22):2005:pp. 14169-14178). cited by examiner Bourgarit et al (AIDS, Jan. 2006, Vo. 20, No. 2, pp. F1-F7). cited by examiner Delgado et al (PNAS, vol. 99, No. 11, May 28, 2002, p. 7576-7581). cited by examiner Greenspan et al. (Nature Biotechnology 7: 936-937, 1999). cited by examiner Bowie et al (Science, 1990, 257:1306-1310). cited by examiner Magnani et al (Clin Exp Immunol 2000, 119:99-106). cited by examiner Mori et al (American Journal of Respiratory and Critical Care Medicine, vol. 170, 2004, pp. 59-64). cited by examiner Boaz et al., “Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection,” J Immunol. Dec. 1, 2002;169(11):6376-85. cited by applicant Bourgarit et al., “Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients.” AIDS (London, England) Jan. 9, 2006, vol. 20, No. 2, Jan. 9, 2006, pp. F1-F7. cited by applicant Delgado et al., “Antigen-specific and persistent tuberculin anergy in a cohort of pulmonary tuberculosis patients from rural Cambodia.” Proceedings of the National Academy of Sciences of the United States of America May 28, 2002, vol. 99, No. 11, May 28, 2002, pp. 7576-7581. cited by applicant Emu et al., “Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment” Journal of Virology Nov. 2005, vol. 79, No. 22, Nov. 2005, pp. 14169-14178. cited by applicant Ewer et al., “Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak” Lancet The, Lancet Limited. London, GB, vol. 361, No. 9364, Apr. 5, 2003, pp. 1168-1173. cited by applicant Fuller et al., “Ablation of CD8 and CD4 T cell responses by high viral loads,” J Immunol. Jan. 1, 2003;170(1):477-86. cited by applicant Guyot-Revol et al., “Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis.” American Journal of Respiratory and Critical Care Medicine Apr. 1, 2006, vol. 173, No. 7, Dec. 9, 2005, pp. 803-810. cited by applicant Harari et al., “Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence.” Journal of Immunology (Baltimore, MD. : 1950) Jan. 15, 2005, vol. 174, No. 2, Jan. 15, 2005, pp. 1037-1045. cited by applicant Harari et al., “Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy,” Blood. Feb. 1, 2004;103(3):966-72. Epub Sep. 4, 2003. cited by applicant Howe et al., “Functional heterogeneity among CD4+ T-cell clones from blood and skin lesions of leprosy patients. Identification of T-cell clones distinct from Th0, Th1 and Th2,” Immunology. Apr. 1995;84(4):585-94. cited by applicant International Preliminary Report on Patentability issued Sep. 23, 2008 during the prosecution of International Application No. PCT/GB2007/000934. Published Sep. 23, 2008. cited by applicant International Search Report issued Sep. 11, 2007 during the prosecution of International Application No. PCT/GB2007/000934. Published Nov. 15, 2007. cited by applicant Lucas et al., “Ex vivo phenotype and frequency of influenza virus-specific CD4 memory T cells,” J Virol. Jul. 2004;78(13):7284-7. cited by applicant Magnani et al., “Circulating, Mycobacterium tuberculosis-specific lymphocytes from PPD skin test-negative patients with tuberculosis do not secrete interferon-gamma (IFN-gamma) and lack the cutaneous lymphocyte antigen skin-selective homing receptor,” Clin Exp Immunol. Jan. 2000;119(1):99-106. cited by applicant Millington et al., “Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load.” Journal of Immunology (Baltimore, MD. : 1950) Apr. 15, 2007, vol. 178, No. 8, Apr. 15, 2007, pp. 5217-5226. cited by applicant Semmo et al., “Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection.” Hepatology (Baltimore, MD.) May 2005, vol. 41, No. 5, May 2005, pp. 1019-1028. cited by applicant Sommer et al., “Analysis of cytokine patterns produced by individual CD4+ lymph node cells during experimental murine leishmaniasis in resistant and susceptible mice,” Int Immunol. Dec. 1998;10(12):1853-61. cited by applicant Sun et al., “Dysfunction of simian immunodeficiency virus/simian human immunodeficiency virus-induced IL-2 expression by central memory CD4+ T lymphocytes,” J Immunol. Apr. 15, 2005;174(8):4753-60. cited by applicant Tsukaguchi et al., “CD4+ alpha beta T cell and gamma delta T cell responses to Mycobacterium tuberculosis. Similarities and differences in Ag recognition, cytotoxic effector function, and cytokine production.” Journal of Immunology (Baltimore, MD. 1950) Feb. 15, 1995, vol. 154, No. 4, Feb. 15, 1995, pp. 1786-1796. cited by applicant United Kingdom Search Report issued Jul. 10, 2006 during the prosecution of Application No. GB0605474.6. cited by applicant Written Opinion issued Sep. 11, 2007 during the prosecution of International Application No. PCT/GB2007/000934. Published Sep. 17, 2008. cited by applicant Younes et al., “HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity,” J Exp Med. Dec. 15, 2003;198(12):1909-22. cited by applicant Eun-Kyeong Jo, et al.; “Dynamics of cytokine generation in patients with active pulmonary tuberculosis”; Current Opinion in Infectious Diseases; 2003; vol. 16; pp. 205-210. cited by applicant European Examination Report, issued Aug. 12, 2009 (published Aug. 12, 2009) during the prosecution of European Application No. 07712923.7. cited by applicant Arend et al., “Antigenic equivalence of human T-cell responses to Mycobacterium tuberculosis-specific RDI-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides,” Infection and Immunity, 68(6):3314-3321, 2000. cited by applicant Jones et al., “Degeneracy of T cell receptor recognition of an influenza virus hemagglutinin epitope restricted by HLA-DQ and -DR class II molecules,” Eur. J. Immunol., 24:1137-1142, 1994. cited by applicant Mustafa et al., “Immunogenicity of Mycobacterium tuberculosis RDI region gene products in infected cattle,” Clin Exp Immunol, 130:37-42, 2002. cited by applicant Okkels et al., “PPE protein (Rv3873) from DNA segment RD1 of Mycobacterium tuberculosis: strong recognition of both specific T-cell epitopes and epitopes conserved within the PPE family,” Infection and Immunity, 71(11):6116-6123, 2003. cited by applicant Shirai et al., “Induction of cytotoxic T cells to a cross-reactive epitope in the hepatitis C virus nonstructural RNA polymerase-like protein,” Journal of Virology, 66(7):4098-4103, 1992. cited by applicant Van der Zee et al., “Efficient mapping and characterization of a T cell epitope by the simultaneous synthesis of multiple peptides,” Eur. J. Immunol., 19:43-47, 1989. cited by applicant Office Action issued in European Application No. 07 712 923.7, mailed Jun. 1, 2011. cited by applicant Caccamo, Nadia, et al.; “Multifunctional CD4” T Cells Correlate with Active Mycobacterium Tuberculosis Infection; Eur. J. Immunol., 2010, vol. 40, pp. 221-2220. cited by applicant Casey, Rosalyn, et al.; “Enumeration of Functional T-Cell Subsets by Fluorescence-Immunospot Defines Signatures of Pathogen Burden in Tuberculosis”; PloS One. Dec. 2010, vol. 5, Issue 12, pp. 1-11. cited by applicant Sester, Urban, et al.; “Whole-Blook Flow-Cytometric Analysis of Antigen-Specific CD4 T-Cell Cytokine Profiles Distinguishes Active Tuberculosis from Non-Active States”: Plos One, Mar. 2011, vol. 6, issue 3. e17813, pp. 1-7. cited by applicant |
| Primary Examiner: | Swartz, Rodney P |
| Attorney, Agent or Firm: | Fulbright & Jaworski LLP |
| Accession Number: | edspgr.08765366 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|